Cytochrome P450-mediated drug metabolism in the brain

Journal of Psychiatry and Neuroscience

Volumn 38, Issue 3, 2013, Pages 152-163

  Miksys, Sharon ^a   Tyndale, Rachel F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; CARCINOGEN; CHLORPYRIFOS; CLONIDINE; CLOZAPINE; CYTOCHROME P450; DESIPRAMINE; DIAZEPAM; DICLOFENAC; DOPAMINE; IMIPRAMINE; KETAMINE; METHADONE; METHOXSALEN; NEUROLEPTIC AGENT; NEUROTOXIN; NICOTINE; PENTOBARBITAL; PETHIDINE; PHENCYCLIDINE; PROPOFOL; PROPRANOLOL; RISPERIDONE; SELEGILINE; SEROTONIN; SERTRALINE; TRAMADOL; TYRAMINE; UNINDEXED DRUG;

ANTIBODY SPECIFICITY; ANTIDEPRESSANT ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; BRAIN PERFUSION; CELL SPECIFICITY; DRUG ABUSE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; ELECTROENCEPHALOGRAM; MICRODIALYSIS; NEUROTOXICITY; PARKINSON DISEASE; PSYCHIATRY;

EID: 84876532667     PISSN: 11804882     EISSN: 14882434     Source Type: Journal    
DOI: 10.1503/jpn.120133     Document Type: Review

References (170)

1. Porcelli S, Fabbri C, Spina E, et al. Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism. Expert Opin Drug Metab Toxicol 2011;7:1101-15.
2. Tekes K, Hashemi F, Szegi P, et al. Prodrugs and active metabolites among antidepressive compounds. Neuropsychopharmacol Hung 2011;13:103-10.
3. D'Empaire I, Guico-Pabia C, Preskorn S. Antidepressant treatment and altered CYP2D6 activity: Are pharmacokinetic variations clinically relevant? J Psychiatr Pract 2011;17:330-9.
4. Leysen JE, Janssen PM, Megens AA, et al. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry 1994;55(Suppl):5-12.
5. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004;369:23-37.
6. Michels R, Marzuk PM. Progress in psychiatry (1). N Engl J Med 1993;329:552-60.
7. Ferguson CS, Tyndale RF. Cytochrome P450 enzymes in the brain: emerging evidence of biological significance. Trends Pharmacol Sci 2011;32:708-14.
8. Dutheil F, Jacob A, Dauchy S, et al. ABC transporters and cytochromes P450 in the human central nervous system: influence on brain pharmacokinetics and contribution to neurodegenerative disorders. Expert Opin Drug Metab Toxicol 2010;6:1161-74.
9. Nelson DR. Progress in tracing the evolutionary paths of cytochrome P450. Biochim Biophys Acta 2011;1814:14-8.
10. Mo SL, Liu YH, Duan W, et al. Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. Curr Drug Metab 2009;10:730-53.
11. Wang H, Tompkins LM. CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab 2008;9: 598-610.
12. Wang B, Yang LP, Zhang XZ, et al. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme. Drug Metab Rev 2009;41:573-643.
13. Dutheil F, Beaune P, Loriot MA. Xenobiotic metabolizing enzymes in the central nervous system: Contribution of cytochrome P450 enzymes in normal and pathological human brain. Biochimie 2008;90:426-36.
14. Rifkind AB. CYP1A in TCDD toxicity and in physiology with particular reference to CYP dependent arachidonic acid metabolism and other endogenous substrates. Drug Metab Rev 2006;38:291-335.
15. Zhou SF, Zhou ZW, Yang LP, et al. Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem 2009;16:3480-675.
16. Ingelman-Sundberg M. Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn Schmiedebergs Arch Pharmacol 2004;369:89-104.
17. Indiana University School of Medicine. P450 drug interaction table. Available: http://medicine.iupui.edu/clinpharm/ddis/table.aspx (accessed 2012 May 9).
18. Cytochrome P450 Knowledgebase, Release 2006. Available: http://cpd.ibmh.msk.su (accessed 2012 May 23).
19. Sridar C, Snider NT, Hollenberg PF. Anandamide oxidation by wild-type and polymorphically expressed CYP2B6 and CYP2D6. Drug Metab Dispos 2011;39:782-8.
20. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet 2009;48:689-723.
21. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet 2009;48:761-804.
22. McGraw J, Waller D. Cytochrome P450 variations in different ethnic populations. Expert Opin Drug Metab Toxicol 2012;8:371-82.
23. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009; 41:89-295.
24. Miksys S, Tyndale RF. The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics. Drug Metab Rev 2004;36:313-33.
25. Miksys S, Lerman C, Shields PG, et al. Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology 2003;45:122-32.
26. Mann A, Miksys SL, Gaedigk A, et al. The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson's disease patients. Neurobiol Aging 2012;33:2160-71.
27. Treluyer JM, Jacqz-Aigrain E, Alvarez F, et al. Expression of CYP2D6 in developing human liver. Eur J Biochem 1991;202:583-8.
28. Parkinson A, Mudra DR, Johnson C, et al. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 2004;199:193-209.
29. Nelson JC, Mazure CM, Jatlow PI. Desipramine treatment of major depression in patients over 75 years of age. J Clin Psychopharmacol 1995;15:99-105.
30. Fishman J, Hahn EF, Norton BI. N-demethylation of morphine in rat brain is localised in sites with high opiate receptor content. Nature 1976;261:64-5.
31. Paul SM, Axelrod J, Diliberto EJ Jr. Catechol estrogen-forming enzyme of brain: demonstration of a cytochrome p450 monooxygenase. Endocrinology 1977;101:1604-10.
32. Sasame HA, Ames MM, Nelson SD. Cytochrome P-450 and NADPH cytochrome c reductase in rat brain: formation of catechols and reactive catechol metabolites. Biochem Biophys Res Commun 1977;78:919-26.
33. Anandatheerthavarada HK, Shankar SK, Ravindranath V. Rat brain cytochromes P-450: catalytic, immunochemical properties and inducibility of multiple forms. Brain Res 1990;536:339-43.
34. Minn A, Ghersi-Egea JF, Perrin R, et al. Drug metabolizing enzymes in the brain and cerebral microvessels. Brain Res Brain Res Rev 1991;16:65-82.
35. Perrin R, Minn A, Ghersi-Egea JF, et al. Distribution of cytochrome P450 activities towards alkoxyresorufin derivatives in rat brain regions, subcellular fractions and isolated cerebral microvessels. Biochem Pharmacol 1990;40:2145-51.
36. Ravindranath V, Anandatheerthavarada HK, Shankar SK. Xenobi- otic metabolism in human brain-presence of cytochrome P-450 and associated mono-oxygenases. Brain Res 1989;496:331-5.
37. Walther B, Ghersi-Egea JF, Minn A, et al. Subcellular distribution of cytochrome P-450 in the brain. Brain Res 1986;375:338-44.
38. Warner M, Kohler C, Hansson T, et al. Regional distribution of cytochrome P-450 in the rat brain: spectral quantitation and contribution of P-450b,e, and P-450c,d. J Neurochem 1988;50:1057-65.
39. Kawashima H, Sequeira DJ, Nelson DR, et al. Genomic cloning and protein expression of a novel rat brain cytochrome P-450 CYP2D18* catalyzing imipramine N-demethylation. J Biol Chem 1996;271:28176-80.
40. Kawashima H, Strobel HW. cDNA cloning of a novel rat brain cytochrome P450 belonging to the CYP2D subfamily. Biochem Biophys Res Commun 1995;209:535-40.
41. Komori M. A novel P450 expressed at the high level in rat brain. Biochem Biophys Res Commun 1993;196:721-8.
42. Wang H, Kawashima H, Strobel HW. cDNA cloning of a novel CYP3A from rat brain. Biochem Biophys Res Commun 1996;221:157-62.
43. Miksys S, Rao Y, Sellers EM, et al. Regional and cellular distribution of CYP2D subfamily members in rat brain. Xenobiotica 2000;30: 547-64.
44. Boopathi E, Anandatheerthavarada HK, Bhagwat SV, et al. Accumulation of mitochondrial P450MT2, NH(2)-terminal truncated cytochrome P4501A1 in rat brain during chronic treatment with beta-naphthoflavone. A role in the metabolism of neuroactive drugs. J Biol Chem 2000;275:34415-23.
45. Howard LA, Miksys S, Hoffmann E, et al. Brain CYP2E1 is induced by nicotine and ethanol in rat and is higher in smokers and alcoholics. Br J Pharmacol 2003;138:1376-86.
46. Miksys S, Rao Y, Hoffmann E, et al. Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics. J Neurochem 2002;82:1376-87.
47. Bhamre S, Anandatheerathavarada HK, Shankar SK, et al. Purification of multiple forms of cytochrome P450 from a human brain and reconstitution of catalytic activities. Arch Biochem Biophys 1993;301:251-5.
48. Farin FM, Omiecinski CJ. Regiospecific expression of cytochrome P-450s and microsomal epoxide hydrolase in human brain tissue. J Toxicol Environ Health 1993;40:317-35.
49. Strobel HW, Geng J, Kawashima H, et al. Cytochrome P450- dependent biotransformation of drugs and other xenobiotic substrates in neural tissue. Drug Metab Rev 1997;29:1079-105.
50. Strömstedt M, Hayashi S, Warner M, et al. Cytochrome P-450 in the brain. Biochem Soc Trans 1990;18:28-30.
51. Miksys S, Hoffmann E, Tyndale RF. Regional and cellular induction of nicotine-metabolizing CYP2B1 in rat brain by chronic nicotine treatment. Biochem Pharmacol 2000;59:1501-11.
52. Upadhya SC, Tirumalai PS, Boyd MR, et al. Cytochrome P4502E (CYP2E) in brain: constitutive expression, induction by ethanol and localization by fluorescence in situ hybridization. Arch Biochem Biophys 2000;373:23-34.
53. Chinta SJ, Kommaddi RP, Turman CM, et al. Constitutive expression and localization of cytochrome P-450 1A1 in rat and human brain: presence of a splice variant form in human brain. J Neurochem 2005;93:724-36.
54. Hagemeyer CE, Rosenbrock H, Ditter M, et al. Predominantly neuronal expression of cytochrome P450 isoforms CYP3A11 and CYP3A13 in mouse brain. Neuroscience 2003;117:521-9.
55. Rosenbrock H, Hagemeyer CE, Ditter M, et al. Expression and localization of the CYP2B subfamily predominantly in neurones of rat brain. J Neurochem 2001;76:332-40.
56. Volk B, Hettmannsperger U, Papp T, et al. Mapping of phenytoin- inducible cytochrome P450 immunoreactivity in the mouse central nervous system. Neuroscience 1991;42:215-35.
57. Norris PJ, Hardwick JP, Emson PC. Regional distribution of cytochrome P450 2D1 in the rat central nervous system. J Comp Neurol 1996;366:244-58.
58. Dutheil F, Dauchy S, Diry M, et al. Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function. Drug Metab Dispos 2009;37:1528-38.
59. Dauchy S, Dutheil F, Weaver RJ, et al. ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood-brain barrier. J Neurochem 2008;107:1518-28.
60. Decleves X, Jacob A, Yousif S, et al. Interplay of drug metabolizing CYP450 enzymes and ABC transporters in the blood-brain barrier. Curr Drug Metab 2011;12:732-41.
61. Mann A, Miksys S, Lee A, et al. Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment. Neuropharmacology 2008;55:1147-55.
62. Bromek E, Haduch A, Daniel WA. The ability of cytochrome P450 2D isoforms to synthesize dopamine in the brain: an in vitro study. Eur J Pharmacol 2010;626:171-8.
63. Bromek E, Haduch A, Golembiowska K, et al. Cytochrome P450 mediates dopamine formation in the brain in vivo. J Neurochem 2011;118:806-15.
64. Rosenbrock H, Hagemeyer CE, Singec I, et al. Testosterone metabolism in rat brain is differentially enhanced by phenytoin-inducible cytochrome P450 isoforms. J Neuroendocrinol 1999;11:597-604.
65. Bertilsson L, Alm C, De Las Carreras C, et al. Debrisoquine hy- droxylation polymorphism and personality. Lancet 1989;1:555.
66. Dorado P, Penas-Lledo EM, Llerena A. CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits. Pharmacogenomics 2007;8:1597-608.
67. Llerena A, Edman G, Cobaleda J, et al. Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr Scand 1993;87:23-8.
68. Roberts RL, Luty SE, Mulder RT, et al. Association between cytochrome P450 2D6 genotype and harm avoidance. Am J Med Genet B Neuropsychiatr Genet 2004;127B:90-3.
69. Kirchheiner J, Seeringer A, Godoy AL, et al. CYP2D6 in the brain: genotype effects on resting brain perfusion. Mol Psychiatry 2011;16: 237, 333-41.
70. Stingl JC, Brockmoller J, Viviani R. Genetic variability of drug- metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function. Mot Psychiatry 2012 May 8. [Epub ahead of print].
71. Ishii G, Suzuki A, Oshino S, et al. CYP2C19 polymorphism affects personality traits of Japanese females. Neurosci Lett 2007;411:77-80.
72. Matsumoto Y, Suzuki A, Shibuya N, et al. Association study of the cytochrome P450 17 gene polymorphism with personality traits in healthy subjects. Behav Brain Res 2008;194:21-4.
73. Matsumoto Y, Suzuki A, Shibuya N, et al. Effect of the cytochrome P450 19 (aromatase) gene polymorphism on personality traits in healthy subjects. Behav Brain Res 2009;205:234-7.
74. Ohtsuka Y, Aoki J, Iwahashi K. [Correlation analyses of ALDH2 and CYP2E1 genetic polymorphism with personality] [Article in Japanese]. Nihon Arukoru Yakubutsu Igakkai Zasshi 2008;43:782-8.
75. Hiroi T, Imaoka S, Funae Y. Dopamine formation from tyramine by CYP2D6. Biochem Biophys Res Commun 1998;249:838-43.
76. Yu AM, Idle JR, Byrd LG, et al. Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 2003;13:173-81.
77. Yu AM, Idle JR, Gonzalez FJ. Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. Drug Metab Rev 2004;36:243-77.
78. Snider NT, Sikora MJ, Sridar C, et al. The endocannabinoid anan- damide is a substrate for the human polymorphic cytochrome P450 2D6. J Pharmacol Exp Ther 2008;327:538-45.
79. Hiroi T, Kishimoto W, Chow T, et al. Progesterone oxidation by cytochrome P450 2D isoforms in the brain. Endocrinology 2001;142: 3901-8.
80. Fradette C, Yamaguchi N, Du Souich P. 5-Hydroxytryptamine is biotransformed by CYP2C9, 2C19 and 2B6 to hydroxylamine, which is converted into nitric oxide. Br J Pharmacol 2004;141:407-14.
81. Miczek KA, Fish EW, De Bold JF. Neurosteroids, GABAA receptors, and escalated aggressive behavior. Horm Behav 2003;44:242-57.
82. Montoya ER, Terburg D, Bos PA, et al. Testosterone, cortisol, and serotonin as key regulators of social aggression: a review and theoretical perspective. Motiv Emot 2012;36:65-73.
83. Konkel A, Schunck WH. Role of cytochrome P450 enzymes in the bioactivation of polyunsaturated fatty acids. Biochim Biophys Acta 2011;1814:210-22.
84. Tyndale RF, Li Y, Li NY, et al. Characterization of cytochrome P-450 2D1 activity in rat brain: high-affinity kinetics for dextromethorphan. Drug Metab Dispos 1999;27:924-30.
85. Coleman T, Spellman EF, Rostami-Hodjegan A, et al. The 1'-hy- droxylation of Rac-bufuralol by rat brain microsomes. Drug Metab Dispos 2000;28:1094-9.
86. Jolivalt C, Minn A, Vincent-Viry M, et al. Dextromethorphan demethylase activity in rat brain microsomes. Neurosci Lett 1995; 187:65-8.
87. Narimatsu S, Yamamoto S, Koitabashi T, et al. Biphasic kinetics of imipramine N-oxidation in rat brain microsomes. Biol Pharm Bull 1999;22:253-6.
88. Albores A, Ortega-Mantilla G, Sierra-Santoyo A, et al. Cytochrome P450 2B (CYP2B)-mediated activation of methyl-parathion in rat brain extracts. Toxicol Lett 2001;124:1-10.
89. Forsyth CS, Chambers JE. Activation and degradation of the phos- phorothionate insecticides parathion and EPN by rat brain. Biochem Pharmacol 1989;38:1597-603.
90. Celotti F, Melcangi RC, Negri-Cesi P, et al. Testosterone metabolism in brain cells and membranes. J Steroid Biochem Mol Biol 1991; 40:673-8.
91. Meyer RP, Lindberg RL, Hoffmann F, et al. Cytosolic persistence of mouse brain CYP1A1 in chronic heme deficiency. Biol Chem 2005;386:1157-64.
92. Meyer RP, Podvinec M, Meyer UA. Cytochrome P450 CYP1A1 accumulates in the cytosol of kidney and brain and is activated by heme. Mol Pharmacol 2002;62:1061-7.
93. Pai KS, Ravindranath V. Protection and potentiation of MPTP- induced toxicity by cytochrome P-450 inhibitors and inducer: in vitro studies with brain slices. Brain Res 1991;555:239-44.
94. Sriram K, Pai KS, Ravindranath V. Protection and potentiation of methyl-4-phenylpyridinium-induced toxicity by cytochrome P450 inhibitors and inducer may be due to the altered uptake of the toxin. J Neurochem 1995;64:1203-8.
95. Hojo Y, Hattori TA, Enami T, et al. Adult male rat hippocampus synthesizes estradiol from pregnenolone by cytochromes P45017alpha and P450 aromatase localized in neurons. Proc Natl Acad Sci U S A 2004;101:865-70.
96. Munetsuna E, Hojo Y, Hattori M, et al. Retinoic acid stimulates 17beta-estradiol and testosterone synthesis in rat hippocampal slice cultures. Endocrinology 2009;150:4260-9.
97. Foster KA, Mellick GD, Weiss M, et al. An isolated in-situ rat head perfusion model for pharmacokinetic studies. Pharm Res 2000;17: 127-34.
98. Foster KA, Weiss M, Roberts MS. Distribution kinetics of solutes in the isolated in-situ perfused rat head using the multiple indicator dilution technique and a physiological two-barrier model. J Pharm Pharmacol 2002;54:373-82.
99. Graham CW, Green AR, Woods HF, et al. 5-Hydroxytryptamine synthesis in the isolated perfused rat brain. Br J Pharmacol 1975;53: 450P-1P.
100. Woods HF, Graham CW, Green AR, et al. Some histological and metabolic properties of an isolated perfused rat brain preparation with special reference to monoamine metabolism. Neuroscience 1976;1:313-23.
101. Sakane T, Nakatsu M, Yamamoto A, et al. Assessment of drug disposition in the perfused rat brain by statistical moment analysis. Pharm Res 1991;8:683-9.
102. Hough LB, Nalwalk JW, Yang J, et al. Brain P450 epoxygenase activity is required for the antinociceptive effects of improgan, a nonopioid analgesic. Pain 2011;152:878-87.
103. Miksys S, Tyndale RF. Brain drug-metabolizing cytochrome P450 enzymes are active in vivo, demonstrated by mechanism-based enzyme inhibition. Neuropsychopharmacology 2009;34:634-40.
104. Koenigs LL, Trager WF. Mechanism-based inactivation of cytochrome P450 2B1 by 8-methoxypsoralen and several other fura- nocoumarins. Biochemistry 1998;37:13184-93.
105. Yanev SG, Kent UM, Roberts ES, et al. Mechanistic studies of cytochrome P450 2B1 inactivation by xanthates. Arch Biochem Biophys 2000;378:157-66.
106. Khokhar JY, Miksys SL, Tyndale RF. Rat brain CYP2B induction by nicotine is persistent and does not involve nicotinic acetylcholine receptors. Brain Res 2010;1348:1-9.
107. Khokhar JY, Tyndale RF. Drug metabolism within the brain changes drug response: selective manipulation of brain CYP2B alters propofol effects. Neuropsychopharmacology 2011;36:692-700.
108. Iohom G, Ni Chonghaile M, O'Brien JK, et al. An investigation of potential genetic determinants of propofol requirements and recovery from anaesthesia. Eur J Anaesthesiol 2007;24:912-9.
109. Shyr MH, Tsai TH, Tan PP, et al. Concentration and regional distribution of propofol in brain and spinal cord during propofol anesthesia in the rat. Neurosci Lett 1995;184:212-5.
110. Favetta P, Degoute CS, Perdrix JP, et al. Propofol metabolites in man following propofol induction and maintenance. Br J Anaesth 2002;88:653-8.
111. Le Guellec C, Lacarelle B, Villard PH, et al. Glucuronidation of propofol in microsomal fractions from various tissues and species including humans: effect of different drugs. Anesth Analg 1995;81: 855-61.
112. Hesse LM, He P, Krishnaswamy S, et al. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 2004;14:225-38.
113. Chimbira W, Sweeney BP. The effect of smoking on postoperative nausea and vomiting. Anaesthesia 2000;55:540-4.
114. Lysakowski C, Dumont L, Czarnetzki C, et al. The effect of cigarette smoking on the hypnotic efficacy of propofol. Anaesthesia 2006;61:826-31.
115. Deng Y, Newman B, Dunne MP, et al. Further evidence that interactions between CYP2D6 and pesticide exposure increase risk for Parkinson's disease. Ann Neurol 2004;55:897.
116. Elbaz A, Levecque C, Clavel J, et al. CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease. Ann Neurol 2004;55:430-4.
117. McCann SJ, Pond SM, James KM, et al. The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: a case-control study and meta-analysis. J Neurol Sci 1997;153:50-3.
118. Alves G, Kurz M, Lie SA, et al. Cigarette smoking in Parkinson's disease: influence on disease progression. Mov Disord 2004;19: 1087-92.
119. Quik M, Huang LZ, Parameswaran N, et al. Multiple roles for nicotine in Parkinson's disease. Biochem Pharmacol 2009;78:677-85.
120. Miksys S, Tyndale RF. Nicotine induces brain CYP enzymes: relevance to Parkinson's disease. J Neural Transm Suppl 2006;(70):177-80.
121. Yue J, Miksys S, Hoffmann E, et al. Chronic nicotine treatment induces rat CYP2D in the brain but not in the liver: an investigation of induction and time course. J Psychiatry Neurosci 2008;33:54-63.
122. Mann A, Tyndale RF. Cytochrome P450 2D6 enzyme neuroprotects against 1-methyl-4-phenylpyridinium toxicity in SH-SY5Y neuronal cells. Eur J Neurosci 2010;31:1185-93.
123. Matoh N, Tanaka S, Takehashi M, et al. Overexpression of CYP2D6 attenuates the toxicity of MPP+ in actively dividing and differentiated PC12 cells. Gene Expr 2003;11:117-24.
124. Steenland K, Dick RB, Howell RJ, et al. Neurologic function among ter- miticide applicators exposed to chlorpyrifos. Environ Health Perspect 2000;108:293-300.
125. Sultatos LG. Mammalian toxicology of organophosphorus pesticides. J Toxicol Environ Health 1994;43:271-89.
126. Tang J, Cao Y, Rose RL, et al. Metabolism of chlorpyrifos by human cytochrome P450 isoforms and human, mouse, and rat liver microsomes. Drug Metab Dispos 2001;29:1201-4.
127. Ellison CA, Crane AL, Olson JR. Biotransformation of insecticides. In: Anzenbacher P, Zanger UM, editors. Metabolism of drugs and other xenobiotics. Weinheim (Germany): Wiley-VCH Verlag & Co.; 2012. p. 685-702.
128. Bushnell PJ, Pope CN, Padilla S. Behavioral and neurochemical effects of acute chlorpyrifos in rats: tolerance to prolonged inhibition of cholinesterase. J Pharmacol Exp Ther 1993;266:1007-17.
129. Khokhar JY, Tyndale RF. Rat brain CYP2B-enzymatic activation of chlorpyrifos to the oxon mediates cholinergic neurotoxicity. Toxicol Sci 2012;126:325-35.
130. Gordon CJ, Grantham TA, Yang Y. Hypothermia and delayed fever in the male and female rat exposed to chlorpyrifos. Toxicology 1997;118:149-58.
131. Health Canada. Canadian Tobacco Use Monitoring Survey 2010. Available: www.hc-sc.gc.ca/hc-ps/tobac-tabac/research-recherche/stat/ctums-esutc_2010-eng.php (accessed 2012 May 15).
132. Khokhar JY, Ferguson CS, Zhu AZ, et al. Pharmacogenetics of drug dependence: role of gene variations in susceptibility and treatment. Annu Rev Pharmacol Toxicol 2010;50:39-61.
133. Hoffmann E, O'Loughlin J, Karp I, et al. CYP2B6 and CYP2A6 genotype: impact on acquisition of ICD10 tobacco dependence in Caucasian adolescents [poster abstract]. Proceedings of the Society for Research on Nicotine and Tobacco 12th Annual Meeting; 2006 Feb. 15-18; Orlando, Fla. Madison (WI): The Society; 2006. p. 108.
134. Lee AM, Jepson C, Hoffmann E, et al. CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. Biol Psychiatry 2007;62:635-41.
135. Shram MJ, Siu EC, Li Z, et al. Interactions between age and the aversive effects of nicotine withdrawal under mecamylamine- precipitated and spontaneous conditions in male Wistar rats. Psychopharmacology (Berl) 2008;198:181-90.
136. Malin DH, Lake JR, Newlin-Maultsby P, et al. Rodent model of nicotine abstinence syndrome. Pharmacol Biochem Behav 1992;43: 779-84.
137. Miksys S, Bahgai F, Tyndale RF. Inhibiting CYP2B, a nicotine metabolizing enzyme, specifically in brain inhibits nicotine withdrawal in rats [abstract]. Proceedings of the Society for Research on Nicotine and Tobacco 16th Annual Meeting; 2010 Feb. 24-27; Baltimore, Md. Madison (WI): The Society; 2010. p. 30.
138. Corrigall WA, Coen KM. Nicotine maintains robust self-administration in rats on a limited-access schedule. Psychopharmacology (Berl) 1989;99: 473-8.
139. Garcia K, Coen KM, Miksys S, et al. Inhibition of brain CYP2B- mediated nicotine metabolism can alter spontaneous acquisition of nicotine self-administration [poster presentation]. Canadian College of Neuropsychopharmacology 35th Annual Meeting; 2012 May 23-26; Vancouver, BC.
140. Funck-Brentano C, Boelle PY, Verstuyft C, et al. Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects. Eur J Clin Pharmacol 2005;61:821-9.
141. Schoedel KA, Sellers EM, Tyndale RF. Induction of CYP2B1/2 and nicotine metabolism by ethanol in rat liver but not rat brain. Biochem Pharmacol 2001;62:1025-36.
142. Lee AM, Miksys S, Palmour R, et al. CYP2B6 is expressed in African Green monkey brain and is induced by chronic nicotine treatment. Neuropharmacology 2006;50:441-50.
143. Joshi M, Tyndale RF. Regional and cellular distribution of CYP2E1 in monkey brain and its induction by chronic nicotine. Neuropharmacology 2006;50:568-75.
144. Haduch A, Bromek E, Daniel WA. The effect of psychotropic drugs on cytochrome P450 2D (CYP2D) in rat brain. Eur J Pharmacol 2011;651:51-8.
145. Hedlund E, Wyss A, Kainu T, et al. Cytochrome P4502D4 in the brain: specific neuronal regulation by clozapine and toluene. Mol Pharmacol 1996;50:342-50.
146. Meyer RP, Gehlhaus M, Schwab R, et al. Concordant up-regulation of cytochrome P450 Cyp3a11, testosterone oxidation and androgen receptor expression in mouse brain after xenobiotic treatment. J Neurochem 2009;109:670-81.
147. Schilter B, Andersen MR, Acharya C, et al. Activation of cytochrome P450 gene expression in the rat brain by phenobarbital-like inducers. J Pharmacol Exp Ther 2000;294:916-22.
148. Marini S, Nannelli A, Sodini D, et al. Expression, microsomal and mitochondrial activities of cytochrome P450 enzymes in brain regions from control and phenobarbital-treated rabbits. Life Sci 2007;80:910-7.
149. Benowitz NL, Hukkanen J, Jacob P 3rd. Nicotine chemistry, metabolism, kinetics and biomarkers. Handb Exp Pharmacol 2009; 192:29-60.
150. Honkakoski P, Negishi M. Regulation of cytochrome P450 (CYP) genes by nuclear receptors. Biochem J 2000;347:321-37.
151. Sonoda J, Rosenfeld JM, Xu L, et al. A nuclear receptor-mediated xenobiotic response and its implication in drug metabolism and host protection. Curr Drug Metab 2003;4:59-72.
152. Tolson AH, Wang H. Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR. Adv Drug Deliv Rev 2010; 62:1238-49.
153. Nishimura M, Naito S, Yokoi T. Tissue-specific mRNA expression profiles of human nuclear receptor subfamilies. Drug Metab Pharmacokinet 2004;19:135-49.
154. Petersen SL, Curran MA, Marconi SA, et al. Distribution of mRNAs encoding the arylhydrocarbon receptor, arylhydrocarbon receptor nuclear translocator, and arylhydrocarbon receptor nuclear translocator-2 in the rat brain and brainstem. J Comp Neurol 2000; 427:428-39.
155. Lamba JK, Lamba V, Yasuda K, et al. Expression of constitutive androstane receptor splice variants in human tissues and their functional consequences. J Pharmacol Exp Ther 2004;311:811-21.
156. Lamba V, Yasuda K, Lamba JK, et al. PXR (NR1I2): splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators. Toxicol Appl Pharmacol 2004;199:251-65.
157. Moreno S, Farioli-Vecchioli S, Ceru MP. Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 2004;123:131-45.
158. Jeninga EH, Gurnell M, Kalkhoven E. Functional implications of genetic variation in human PPARgamma. Trends Endocrinol Metab 2009;20:380-7.
159. Koyano S, Saito Y, Fukushima-Uesaka H, et al. Functional analysis of six human aryl hydrocarbon receptor variants in a Japanese population. Drug Metab Dispos 2005;33:1254-60.
160. Lamba J, Lamba V, Schuetz E. Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. Curr Drug Metab 2005;6:369-83.
161. Xiao L, Xie X, Zhai Y. Functional crosstalk of CAR-LXR and ROR- LXR in drug metabolism and lipid metabolism. Adv Drug Deliv Rev 2010;62:1316-21.
162. Grabowski PJ, Black DL. Alternative RNA splicing in the nervous system. Prog Neurobiol 2001;65:289-308.
163. Lipscombe D. Neuronal proteins custom designed by alternative splicing. Curr Opin Neurobiol 2005;15:358-63.
164. Turman CM, Hatley JM, Ryder DJ, et al. Alternative splicing within the human cytochrome P450 superfamily with an emphasis on the brain: The convolution continues. Expert Opin Drug Metab Toxicol 2006;2:399-418.
165. Kommaddi RP, Turman CM, Moorthy B, et al. An alternatively spliced cytochrome P4501A1 in human brain fails to bioactivate polycyclic aromatic hydrocarbons to DNA-reactive metabolites. J Neurochem 2007;102:867-77.
166. Gomez A, Ingelman-Sundberg M. Epigenetic and microRNA- dependent control of cytochrome P450 expression: a gap between DNA and protein. Pharmacogenomics 2009;10:1067-76.
167. Klaassen CD, Lu H, Cui JY. Epigenetic regulation of drug processing genes. Toxicol Mech Methods 2011;21:312-24.
168. Rukov JL, Shomron N. MicroRNA pharmacogenomics: post- transcriptional regulation of drug response. Trends Mol Med 2011;17:412-23.
169. Anderson MD, Bandiera SM, Chang TK, et al. Effect of androgen administration during puberty on hepatic CYP2C11, CYP3A, and CYP2A1 expression in adult female rats. Drug Metab Dispos 1998; 26:1031-8.
170. Dvorak Z, Pavek P. Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev 2010;42:621-35.